SEC Form SC 13G filed by Organogenesis Holdings Inc.

2/9/24 4:09:35 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORGO alert in real time by email

SC 13G 1 OrganogenesisHoldingsORGO.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Organogenesis Holdings Inc. ----------------------------------------------------- (Name of Issuer) Class A Common Stock ----------------------------------------------------- (Title of Class of Securities) 68621F102 ----------------------------------------------------- (CUSIP Number) December 31, 2023 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.68621F102 13G Page 2 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 11,500,855 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 11,505,331 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 11,505,331 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 8.7% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.68621F102 13G Page 3 of 8 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley & Co. LLC I.R.S. # 13-2655998 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 11,478,036 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 11,478,036 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 11,478,036 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 8.7% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: BD, CO -------------------------------------------------------------------------------- CUSIP No.68621F102 13G Page 4 of 8 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: Organogenesis Holdings Inc. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 85 DAN ROAD CANTON MA 02021 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley (2) Morgan Stanley & Co. LLC -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 (2) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. (2) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Class A Common Stock -------------------------------------------------------------- (e) CUSIP Number: 68621F102 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [x] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.68621F102 13G Page 5 of 8 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of December 31, 2023.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit 99.2 Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.68621F102 13G Page 6 of 8 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 09, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY Date: February 09, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC -------------------------------------------------------------------- Morgan Stanley & Co. LLC EXHIBIT NO. EXHIBITS PAGE ----------- ---------- ---- 99.1 Joint Filing Agreement 7 99.2 Item 7 Information 8 * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.68621F102 13G Page 7 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT --------------------------------------------------- February 09, 2024 --------------------------------------------------- MORGAN STANLEY and Morgan Stanley & Co. LLC hereby agree that, unless differentiated, this Schedule 13G is filed on behalf of each of the parties. MORGAN STANLEY BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley Morgan Stanley & Co. LLC BY: /s/ Christopher O'Hara --------------------------------------------------------------------- Christopher O'Hara/Authorized Signatory, Morgan Stanley & Co. LLC * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001). CUSIP No.68621F102 13G Page 8 of 8 Pages -------------------------------------------------------------------------------- EXHIBIT NO. 99.2 ------------------ ITEM 7 INFORMATION The securities being reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley.

Get the next $ORGO alert in real time by email

Recent Analyst Ratings for

$ORGO

Date	Price Target	Rating	Analyst
6/28/2024	$5.00	Buy	Lake Street
2/7/2024	$5.00	Overweight	Cantor Fitzgerald
6/15/2023	$5.00	Equal-Weight	Morgan Stanley
5/24/2023	$10.00	Neutral → Buy	BTIG Research
11/10/2022		Buy → Neutral	BTIG Research
8/10/2022		Outperform → Perform	Oppenheimer
11/10/2021	$26.00 → $20.00	Outperform	SVB Leerink
8/10/2021	$24.00 → $25.00	Outperform	Credit Suisse

More analyst ratings

SEC Form SC 13G filed by Organogenesis Holdings Inc.

2/9/24 4:09:35 PM ET

$ORGO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ORGO alert in real time by email

Recent Analyst Ratings for

$ORGO

Date	Price Target	Rating	Analyst
6/28/2024	$5.00	Buy	Lake Street
2/7/2024	$5.00	Overweight	Cantor Fitzgerald
6/15/2023	$5.00	Equal-Weight	Morgan Stanley
5/24/2023	$10.00	Neutral → Buy	BTIG Research
11/10/2022		Buy → Neutral	BTIG Research
8/10/2022		Outperform → Perform	Oppenheimer
11/10/2021	$26.00 → $20.00	Outperform	SVB Leerink
8/10/2021	$24.00 → $25.00	Outperform	Credit Suisse

More analyst ratings

SEC Form SC 13G filed by Organogenesis Holdings Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ORGO

SEC Form SC 13G filed by Organogenesis Holdings Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $ORGO

$ORGO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

$ORGO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 271 shares, decreasing direct ownership by 0.14% to 189,525 units (SEC Form 4)

Director Driscoll Michael Joseph sold $127,535 worth of shares (25,000 units at $5.10), decreasing direct ownership by 13% to 166,879 units (SEC Form 4)

$ORGO Press Releases

Fastest customizable press release news feed in the world

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

$ORGO SEC Filings

Organogenesis Holdings Inc. filed SEC Form 8-K: Leadership Update

SEC Form DEF 14A filed by Organogenesis Holdings Inc.

SEC Form 10-Q filed by Organogenesis Holdings Inc.

$ORGO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Organogenesis with a new price target

Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

Morgan Stanley initiated coverage on Organogenesis with a new price target

$ORGO Financials

Live finance-specific insights

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

$ORGO Leadership Updates

Live Leadership Updates

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

$ORGO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Organogenesis Holdings Inc.

Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

Recent Analyst Ratings for
$ORGO

Recent Analyst Ratings for
$ORGO

$ORGO
Insider Purchases

$ORGO
Insider Trading

$ORGO
Press Releases

$ORGO
SEC Filings

$ORGO
Analyst Ratings

$ORGO
Financials

$ORGO
Leadership Updates

$ORGO
Large Ownership Changes